Francisco Roche, 35, pleaded guilty in February to conspiracy to distribute PCP and to unlawful possession of a firearm by a ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

The decision to advance prasinezumab to Phase III was based on results from the Phase IIb PADOVA trial, which demonstrated ...

Roche discontinued the commercial and clinical use of Elevidys after two cases of fatal acute liver failure. The Swiss ...

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Mathieu Roche discusses the role of identity in digital advertising performance, emphasizing transparent data collection and ...

Roche and AbbVie have come up short again in their effort to gain an additional indication for their blockbuster blood cancer ...